The latest price target for Dianthus Therapeutics (NASDAQ:DNTH) was reported by HC Wainwright & Co. on August 12, 2024. The analyst firm set a price target for $40.00 expecting DNTH to rise to within 12 months (a possible 41.34% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Dianthus Therapeutics (NASDAQ:DNTH) was provided by HC Wainwright & Co., and Dianthus Therapeutics reiterated their buy rating.

There is no last upgrade for Dianthus Therapeutics

There is no last downgrade for Dianthus Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dianthus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dianthus Therapeutics was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Dianthus Therapeutics (DNTH) rating was a reiterated with a price target of $40.00 to $40.00. The current price Dianthus Therapeutics (DNTH) is trading at is $28.30, which is out of the analyst’s predicted range.